Arax Advisory Partners’s Atossa Therapeutics ATOS Stock Holding History

Arax Advisory Partners’s Portfolio ATOS Stock Details ATOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3	Closed	-$25	–	3813
2025 Q4	$25	Hold	3	–	–	﹤0.01%	4005
2025 Q3	$36	Buy	+3	New	+$37	﹤0.01%	3548

Other funds holding ATOS

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Arax Advisory Partners's ATOS Position: Q1 2026 in Review

Arax Advisory Partners sold out of Atossa Therapeutics (ATOS) in Q1 2026, closing a stake of 3 shares — an estimated $25 sold.

Arax Advisory Partners first reported a position in ATOS in Q3 2025 and held it in 2 quarters. The position peaked at $36 in Q3 2025. 33 funds tracked by Wall St. Rank hold ATOS as of Q1 2026.

Arax Advisory Partners reported no remaining Atossa Therapeutics position as of Q1 2026 after selling out during the quarter.
Arax Advisory Partners sold 3 Atossa Therapeutics shares in Q1 2026, an estimated $25.
Arax Advisory Partners first reported a position in Atossa Therapeutics in Q3 2025 and held it in 2 quarters.
Arax Advisory Partners's Atossa Therapeutics position peaked at $36 in Q3 2025.
33 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.